Reuters logo
Pfizer Q3 profit beats estimates; oncology drugs shine
October 29, 2013 / 11:11 AM / 4 years ago

Pfizer Q3 profit beats estimates; oncology drugs shine

Oct 29 (Reuters) - Pfizer Inc reported better-than-expected third-quarter earnings on Tuesday, helped by costs cuts and growing sales of recently approved cancer medicines.

The largest U.S. drugmaker said it earned $2.59 billion, or 39 cents per share, in the quarter, compared with $3.21 billion, or 43 cents per share, in the year-earlier period.

Excluding special items, Pfizer earned 58 cents per share. Analysts, on average, expected 56 cents per share, according to Thomson Reuters I/B/E/S.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below